Gretchen Genevieve Kimmick

Breast cancer; treatment of breast cancer; management of menopausal symptoms in breast cancer survivors; survivorship issues after breast cancer; supportive care in managment of cancer patients; breast cancer and treatment of cancer in older persons; diagnosis and management of cancer in underserved populations.

Current Appointments & Affiliations

Professor of Medicine · 2018 - Present Medicine, Medical Oncology, Medicine

Member of the Duke Cancer Institute · 2004 - Present Duke Cancer Institute, Institutes and Centers

In the News

Published December 9, 2015

Older Breast Cancer Patients Defy Survival Models

Published August 18, 2015

Side effects may lead breast cancer patients to skip drugs

View All News

Recent Publications

Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.

Journal Article Breast Cancer Res Treat · April 2025 PURPOSE: While previous research has highlighted treatment delay inequities in early-stage breast cancer and identified potential contributing factors, there is limited research on disparities in treatment delays for metastatic breast cancer (MBC). This st ... Full text Link to item Cite

Web-Based Pain Coping Skills Training (PCST) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol.

Journal Article Contemp Clin Trials · February 2025 BACKGROUND: Aromatase inhibitors (AIs) are a cornerstone of adjuvant systemic therapy for postmenopausal patients with hormone-receptor positive (HR+) breast cancer. Although AIs decrease cancer recurrence rates and improve survival rates, approximately 50 ... Full text Link to item Cite

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered.

Journal Article Clin Drug Investig · February 2025 BACKGROUND AND OBJECTIVE: Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy (ET) significantly enhance progression-free survival and overall survival in patients diagnosed with HR+/HER2- metastatic breast cancer (MBC). Howev ... Full text Link to item Cite

View All Publications

Recent Grants

A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)

Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2023 - 2028

Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence caused by Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial

ResearchCo Investigator · Awarded by Northwestern University · 2022 - 2027

Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated with Tucatinib

ResearchCo Investigator · Awarded by Pfizer, Inc. · 2025 - 2026

View All Grants

Education, Training & Certifications

Wake Forest University · 2000 M.S.

Wake Forest University · 1989 M.D.